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Summary
Objectives: Cannabis is the most widely used illicit drug globally and its use 
has been linked to an increased risk for psychotic disorders. An association 
between cannabis consumption and psychotic symptoms was consistently re-
ported by several studies. This case-control study aimed to widen the current 
findings about the impact of cannabis exposure on the risk of psychosis, by 
investigating the pattern of cannabis consumption in a sample of first-episode 
of psychosis (FEP) patients compared to healthy controls. 
Material and methods: 68 individuals who presented for the first time to mental 
health services of Palermo (Italy) with an ICD-10 diagnosis of psychotic disor-
ders and 74 healthy were enrolled as part of the Sicilian Genetics and Psycho-
sis study. Psychopathological assessment and diagnosis were carried out by 
the Schedule for Clinical Assessment in Neuropsychiatry (SCAN). Socio-demo-
graphic data were collected by the modified version of the Medical Research 
Council (MRC) socio-demographic scale. All participants were interviewed using 
the Cannabis Experience Questionnaire – Modified Version to obtain a detailed 
assessment of lifetime patterns of cannabis and other illicit drug consumption. 
Logistic regression was applied to investigate the relationships between various 
aspects of cannabis use (lifetime use, age at first use, duration, and frequency of 
use) and case-control status while controlling for potential confounders. 
Results: Patients started cannabis consumption about 3 years earlier than 
the control group (t = 3.1, p = 0.002) and were 8 times more likely to having 
started using cannabis before 15 years (adjusted OR = 8.0, 95% CI 2.4-27) 
than controls. Furthermore cases were more likely to smoke more frequently 
than controls (adjusted OR = 4.4, 95% CI 1.08-18). We did not find a difference 
in duration of cannabis use between cases and controls. 
Conclusions: The findings suggest that cannabis exposure, and especially 
daily cannabis consumption, is associated with the risk for psychosis; however, 
the retrospective study design does not allow drawing firm conclusions about 
causality. 
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Introduction
Cannabis exposure has been associated to an increased risk of devel-
oping psychosis. Cannabis is the most popular illicit drug worldwide, and 
although most people who smoke cannabis do not become psychotic, 
evidence from the literature supports an association between cannabis 
use and an increased risk of developing a psychotic disorder 1 2.
The main psychoactive component, which is responsible of the psycho-
togenic effect of cannabis, is Δ9-tetrahydrocannabinol (Δ9-THC). The 
other main constituent of cannabis is cannabidiol (CBD) which has an-
tianxiety and antipsychotic properties 3 4. Recently, high potency varie-
ties of cannabis, such as “skunk” (sensimilla), have become available in 
the market over much of Europe. Such varieties of cannabis contain a 
high concentration of THC and a lower proportion of CBD which seems 
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to “balance” the psychotogenic effect of the former 3 4. 
Cannabis intoxication can cause brief psychotic 
episodes or may exacerbate pre-existing psychotic 
symptoms  5 6. It has been shown that healthy peo-
ple who are administered THC intravenously were 
more likely to develop transient psychotic-like expe-
riences and that THC worsens psychotic symptoms 
in people suffering from psychosis 7. THC exerts its 
psychotogenic role by modulating the dopamine neu-
rotransmission, which is involved in development of 
psychotic symptoms.
The first report suggesting that cannabis might be a 
risk factor for psychosis was the Swedish Conscript 
study. This was a 15 year follow-up of a cohort of 
45.570 conscripts into the armed forces. The risk of 
schizophrenia was 2.3 fold higher among subjects 
who had used cannabis by 18 years and there was 
a dose response relationship, as the risk of develop-
ing schizophrenia was even higher in those who had 
smoked cannabis more frequently  8. Subsequently, 
a series of cohort studies have shown that cannabis 
use generally predates psychosis  9-13. For instance, 
the Dunedin cohort study reported that children and 
adolescents who had used cannabis by the age of 15 
years were 4.5 times more likely to develop schizo-
phreniform psychosis at the age of 26 years  9. van 
Os et al. reported a three times higher risk of devel-
oping psychotic symptoms in the general population 
associated to cannabis consumption  12. Two meta-
analyses concluded that cannabis consumption was 
associated with approximately two-fold increased 
risk of developing a psychotic disorder 1 2. 
Individuals who showed any evidence of psychosis 
proneness appear especially vulnerable, as those 
who started using cannabis in early adolescence. A 
meta-analysis by Large et al. supported the associa-
tion between cannabis consumption and an earlier 
age at first presentation of psychosis 14. Other stud-
ies confirmed that cannabis use is associated to an 
earlier age at first presentation of schizophrenia and 
that there is an interaction between cannabis use 
and gender difference in age at first presentation, in 
the way that the difference by gender in age at first 
presentation is reduced in cannabis users  15. Fur-
thermore, recent evidence shows that high potency 
cannabis and higher frequency of use are associated 
with a higher risk of developing psychosis 3. 
However, only a small proportion of cannabis users 
develop psychotic symptoms or schizophrenia. Can-
nabis users who develop psychosis may have an un-
derlying genetic susceptibility, and some gene poly-
morphisms have been associated to an increased 
risk to develop psychosis  16-21; nevertheless, these 
results need to be further replicated. 
Materials and methods
The Sicilian Genetic and Psychosis (SGAP) study is 
an incidence and a case-control study, carried on by 
the Psychiatric Section of Palermo University Depart-
ment of Experimental Biomedicine and Clinical Neu-
rosciences (BioNeC), aimed at identifying the role of 
putative genetic and environmental risk factors for 
psychosis, including cannabis.
In this work the focus will be on the impact of canna-
bis exposure on the risk of psychoses. Specifically, 
we aimed to compare patterns of cannabis consump-
tion between cases and controls (exposure to can-
nabis lifetime, age at first use, duration of cannabis 
consumption, total number of times used, frequency 
of use) and to discuss the impact of cannabis expo-
sure on psychosis risk in Palermo. 
Participants
A screening of cases aged between 18-65 years af-
fected by any psychoses was run on all the subjects 
presenting to the mental health services of Palermo 
with a first-episode of psychosis (FEP) in a three-year 
period. 204 patients at their first-episode of psycho-
sis (defined as the first contact with psychiatric ser-
vices) were identified.
Inclusion criteria for cases were:
• presence of symptoms of any psychosis such as 
delusions, hallucinations, thought disorder, bizarre 
or disturbed behaviour, negative symptoms, ma-
nia;
• residence in Palermo;
• first ever contact with psychiatric services for psy-
chotic symptoms;
• age between 18 and 65 years;
• absence of an organic cause of psychosis and se-
vere learning disability;
• diagnosis of ICD-10 criteria for schizophrenia (F20), 
other non-affective psychoses (F21-29) or affective 
psychoses (F30-33). 
Cases were excluded if they met any of the following 
criteria: 
• presence of an organic cause underlying psychotic 
symptoms;
• previous contact with mental health services for an 
episode of psychosis; 
• age under 18 or over 65;
• presence of psychotic symptoms resulting from 
acute intoxication as defined by ICD-10 criteria.
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A case control analysis was performed in a sub-
sample of 68 cases (out of the 204 identified for the 
incidence study) that were compared to 74 healthy 
controls. The control sample was recruited from the 
same catchment area as cases, through leaflet distri-
butions and Internet and newspaper advertisements, 
and was representative of the general population at 
risk for the disease.
Measures
The assessment of cases was performed by the fol-
lowing instruments:
• the Schedule for Clinical Assessment in Neuropsy-
chiatry (SCAN)  22 was used to assess psychopa-
thology and to define the diagnosis of psychosis; 
• a modified version of the MRC Socio-demograph-
ic Schedule  23 adapted to the Italian context was 
used to collect socio-demographic data (age, gen-
der, ethnicity, level of education, and occupational 
status);
• the Cannabis Experience Questionnaire – Modified 
Version (CEQmv) 3 was administered to collect data 
on cannabis and other illicit drugs consumption. 
The questionnaire explores cannabis consumption 
in details, including: age at first use, lifetime can-
nabis consumption, current cannabis consumption 
(defined as cannabis consumption within the four 
weeks before the assessment), frequency of use, 
duration of use in years (more or less than 5 years), 
other drugs consumption (including all illicit drugs, 
among which stimulants, tobacco, and alcohol).
Controls were administered the same instruments 
as cases except the SCAN and they were asked to 
complete the Psychosis Screening Questionnaire 
(PSQ) 24 to exclude the presence of a current or past 
psychotic disorder. 
Ethics
The study was approved by the Ethical Committee of 
the Palermo University Medical School and the data 
collection in the mental health services has been au-
thorized by the Department of Mental Health of Paler-
mo which coordinates all the psychiatric services in-
volved in the study. The work has been performed in 
accordance with the principles of the 1983 Declara-
tion of Helsinki. Study participants were asked to sign 
a consent form before attending the interview.
Analyses
Patterns of cannabis use in cases and controls were 
investigated using, where appropriate, χ2-test or Fish-
er exact test (cannabis use lifetime, current cannabis 
use, frequency of cannabis use, use before and after 
15 years). Welch test and Wilcoxon tests were used 
to calculate mean age at first use and mean duration 
of cannabis use for cases and controls because of 
unequal variances. ANOVA was used to evaluate dif-
ferences in the mean age of first cannabis consump-
tion by case-control status. Logistic regression was 
used to analyze the association between the pattern 
of cannabis use and the risk of psychosis, control-
ling for possible confounders. Confounders were se-
lected as the main socio-demographic differences 
between cases and controls that might influence the 
risk of psychosis (age, gender, level of education, 
occupational status, psychiatric family history, and 
other drug use). 
Results
Socio-demographic characteristics of cases and 
controls are displayed in Table I.
Table II summarizes differences in patterns of cannabis 
consumption between cases and controls. In Palermo 
sample, patients were not more likely than controls to 
have smoked cannabis at least once, lifetime (OR = 
0.4, 95% CI 0.1-1.1) and this may reflect that cannabis 
consumption is quite spread in the general population. 
No differences in lifetime cannabis consumption by 
gender both in cases (χ2 = 1.4, df = 1, p = 0.238) and 
controls (χ2 = .8, df = 1, p = 0.178) were found. 
After adjusting for possible confounders (age, gen-
der, education, occupational status, psychiatric 
family history, and other drugs abuse) cases were 
over 5 times (adjusted OR = 5.4 ,95% CI 1.2-24.1) 
more likely than controls to be current cannabis 
consumers (meaning having smoked cannabis in 
the previous four weeks). In addition, mean age at 
first use of cannabis differed between cases and 
controls. Patients started cannabis consumption 
about 3 years earlier than controls (Welch test 
t = 3.1, df = 60, p = 0.002). 
Accordingly to the existing literature, age of 15 years 
old might be a critical age of first exposure 25 26; there-
fore, we investigated the odds of being a case having 
been exposed to cannabis “before 15 years of age”. 
We found that cases were 8 times more likely than 
controls to having started using cannabis before 15 
years (adj. OR = 8, 95% CI 2.4-27).
Furthermore, previous literature on cannabis expo-
sure in FEP patients reported that cases were about 
six times more likely than controls to use cannabis 
every day  3. In Palermo sample, frequency of can-
nabis consumption in cannabis users was coded as 
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“frequent” (e.g. everyday use and more than 3 times 
a week) and “sporadic” (meaning that the subject 
tried cannabis only once or twice lifetime, a few times 
each month and a few times each year). Cases who 
were cannabis consumers were more likely to smoke 
more frequently than controls (adj. OR  =  4.4, 95% 
CI 1.08-18). Frequency of cannabis use was further 
analysed in terms of “daily use” as opposite to “less 
than daily use”. Consistently with a previous study in 
an UK sample of FEP 3, in our sample cases were 7.5 
times more likely to smoke cannabis everyday com-
pared to controls (χ2 = 9.4, df = 1, p-value = 0.004; 
adj. OR = 7.5, 95% CI 1.9-29.7).
Moreover, we compared the total number of times that 
cases and controls had smoked cannabis lifetime (“up 
to 50 times” versus “between 50 and over 200 times”) 
and we found that patients were more likely than con-
trols to have used cannabis between 50 and over 200 
times (adj. OR = 5.0, 95% CI 1.5-16.4). 
We did not find a difference in duration of use of 
cannabis use between cases and controls. Mean 
duration of cannabis consumption was 7.4 years for 
cases and 6.8 years for controls (Welch test t = -0.3, 
df = 45, p = 0.785). 
Table I. Sample characteristics of cases and controls.
Cases
(n = 68) 
Controls 
(n = 74)
p*
Age, years mean (sd)
Median (IQR)
No details 
28.25 (11.2)
24 (13)
-
36 (13.2)
33.5 (28)
-
< 0.001
Gender, n (%)
Male
Female 
No details
44 (64.7)
24 (35.3)
-
39 (52.7)
35 (47.3)
-
0.147
IQ (WAIS) mean (sd)
No details
78.71 (16.81)
34
101.58 (23.05)
-
< 0.001
Migration status, n (%)
Natives
Migrant
No details
60 (88.2)
8 (11.8)
-
70 (94.6)
4 (5.4)
-
0.174
Ethnicity, n (%)
Caucasian 
Non Caucasian 
No details
64 (94.1)
4 (5.9)
-
71 (95.95)
3 (4.05)
-
0.710
Level of education, n (%)
No education
Primary school 
Junior High
Diploma 
University 
No details
0
9 (13.4)
26 (38.8)
30 (44.8)
2 (3)
1
2 (2.7)
1 (1.4)
13 (17.8)
47 (64.4)
10 (13.7)
1
< 0.001
Mean age left education, sd
No details
16 (2.91)
1
19.3 (3.5)
1
< 0.001
Employment, n (%)
Unemployed
Employed
Student
Retired
No details
41 (61.2)
14 (20.9)
12 (17.9)
0
1
17 (23)
35 (47.3)
11 (14.9)
11 (14.9)
-
< 0.001
Relationship status, n (%) 
In a stable relationship
Single/separated/divorced
No details
14 (20.6)
54 (79.4)
-
47 (63.5)
27 (36.5)
-
< 0.001
* p value from χ2 tests, Fisher’s tests, t test, Wilcoxon test.
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Discussion 
We found that in the Palermo sample lifetime can-
nabis exposure was similar in patients and in healthy 
controls. However, lifetime cannabis use does not 
say much about the extent of exposure to cannabis, 
since it is likely that some people only tried cannabis 
a few times in their life. A more significant index of 
cannabis exposure is cannabis consumption before 
the onset of psychosis; in this work we considered 
“cannabis consumption at the time of assessment”. 
Cases were 5 times more likely than controls to be 
current users at the time of assessment, and this 
suggests that patients may have smoked more re-
cently than healthy controls but it does not really give 
any information on the degree of cannabis exposure. 
As reported in the literature, there is a dose-response 
relationship between cannabis consumption and risk 
of psychotic disorder 2. Frequency is one of the pa-
rameters of cannabis consumption that can modulate 
the risk for psychosis 26. In the Palermo sample, cas-
es who smoked cannabis were four time more likely 
to be frequent users than controls, who tended to 
use cannabis in more a sporadic way. Furthermore, 
in line with the GAP study findings 3, cases were 7.5 
times more likely to smoke cannabis everyday com-
pared to controls. While these results confirm the role 
of frequency of cannabis use in increasing the risk of 
developing psychotic disorder, they prevent any firm 
conclusions about direction of causality. However, a 
meta-analysis of prospective studies demonstrated 
that the effect of cannabis use on psychosis was not 
fully accounted by prodromal psychotic symptoms 
that may had driven cannabis use, and did not simply 
reflect the acute psychotogenic effect of cannabis 10. 
Arsenault et al. reported an association between 
earlier age at first cannabis use and a higher risk of 
schizophrenia  9. In Palermo sample, cases started 
smoking cannabis significantly earlier than controls; 
in fact, cases were more likely than healthy controls 
to have started cannabis consumption before the age 
of 15 years. This is interesting because some authors 
suggested that cannabis consumption may impact 
on brain development, and that early adolescence 
may, therefore, be a critical period for effects that do 
not occur when exposure begins later 27.
These results confirm the different pattern of can-
nabis consumption in people affected by psychosis 
and this may lead to consider cannabis as a contrib-
uting factor in the aetiology of psychotic disorders. 
Table II. Patterns of cannabis use in cases and controls.
Cases
(n = 68) 
Controls 
(n = 74)
p*
Cannabis use lifetime, n (%)
Yes
No 
No details
29 (44.6)
36 (55.4)
3
42 (56.76)
32 (43.2)
0
0.153
Current cannabis use* (at the time of the assessment), n (%)
Yes 
No†
No details
14 (51.85)
13 (48.15)
2
9 (21.4)
33 (78.5)
0
0.009
Frequency of cannabis use, n (%)
Everyday 
Less than everyday
No details
12 (44.4)
15 (55.5)
2
4 (10.8)
33 (89.2)
5
0.003
Total number of time used, n (%)
< 50 times
> 50 and over 200
No details
7 (27)
19 (73)
3
22 (59.46)
15 (40.54)
5
0.011
Age of first use, mean (sd) 16 (2.34) 19 (5.37) 0.002
Mean duration cannabis, years, (sd) 7.4 (7) 6.8 (7.67) 0.670
*p value from χ2 tests, Fisher’s tests, t test, Wilcoxon test. †No current use was defined as no cannabis consumption in the previous 4 weeks 
as reported in the GAP study. The first row refers to all the sample of cases and controls while the following rows of the tables refer only to the 
subgroup of cannabis smokers in cases (n = 29) and controls (n = 42).
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We controlled for the role of possible confounders 
as socio-demographic (age, gender, level of educa-
tion and employment) and other environmental risk 
factors (other drug use and stimulant use). Demon-
strating that frequency of use and early cannabis 
consumption is associated to an increased risk of 
psychosis may have relevance in public health pre-
vention strategies and in organizing specific educa-
tional programs for adolescents. 
This study has some limitations. Only one third of 
the FEP cases identified in the incidence part of the 
study were recruited in the case control analyses, 
but reassuringly there were not significant differ-
ences in terms of gender, ethnicity migration, level 
of education between participants and non-partic-
ipants. For the selection of controls, an effort has 
been made to get a representative sample of the 
general population and controls were similar on a 
number of socio-demographic factors (age, gender, 
migrant status, level of education) to the population 
the cases come from. We do not think that selec-
tion bias might have influenced the results. A fur-
ther source of bias is recall bias, because the in-
formation on the exposure was collected after the 
disease onset. However, it is unlikely that cannabis 
consumption was under-reported in our sample; in 
fact, lifetime cannabis consumption – both in cases 
(44%) and controls (56.7%) –  was  higher than in 
the Italian general population (22%). Furthermore, 
previous studies explored the impact of cannabis 
potency on psychosis risk 3, in our sample however, 
we did not have the chance to measure the effect of 
low and high potency kinds of cannabis due to the 
low exposure in Palermo to high potency cannabis 
(only 3 cases and 4 controls had ever tried high po-
tency cannabis).
Conclusions
In the present study patients were more likely than 
healthy controls to have started to smoke cannabis be-
fore 15 years, and to have a higher frequency of use.
Our data support an association between cannabis 
exposure and especially of everyday cannabis con-
sumption and the risk of psychosis; however we are 
aware that the retrospective study design does not 
allow drawing definite conclusions about direction 
of causality. 
Take home messages for psychiatric care
• Frequent cannabis use may increase the risk of developing psychosis
• Smoking cannabis in early adolescence may lead to psychosis
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